Financialisation: a 21st century commercial determinant of health equity

dc.contributor.authorFriel, Sharonen
dc.contributor.authorSchram, Ashleyen
dc.contributor.authorFrank, Nicholasen
dc.contributor.authorArthur, Meganen
dc.contributor.authorTownsend, Belindaen
dc.contributor.authorGajurel, Hrideshen
dc.date.accessioned2025-05-30T22:31:57Z
dc.date.available2025-05-30T22:31:57Z
dc.date.issued2024en
dc.description.abstractIn 21st century capitalism, financial markets reign supreme. The elevation of investing, trading, and speculating as a way of making profit has shifted economic power towards institutional investors and enhanced the power of financial capital. Financialisation has introduced uncertainty in the commitment to public provision of goods and services. The behaviours of corporations focus more on profit for shareholders and senior executives to the detriment of wages, worker protections, livelihoods, and impact on prices and the environment. The practices of this financial system pose major challenges to public health and planetary health equity through the influence on social inequality, climate change, and health outcomes. The aim of this Viewpoint is to expand the understanding of the commercial determinants of health to explicitly include the financial system and present key plausible pathways via which the financialisation of advanced economies influences public health and planetary health equity. The global public health community must pay close attention to these key commercial determinants of health. It is now crucial to reduce the power of financial actors and hold financial actors accountable. Civil society groups can highlight their practices, articulate alternative visions, and hold financial actors and governments to account. Interdisciplinary research must provide a diagnosis of the financial and public health issues, and, importantly, illuminate effective pathways forward. Financial and commercial worlds must return to stakeholder primacy rather than that of the shareholder.en
dc.description.statusPeer-revieweden
dc.format.extent4en
dc.identifier.issn0140-6736en
dc.identifier.otherORCID:/0000-0002-8345-5435/work/166932047en
dc.identifier.otherORCID:/0000-0001-6385-698X/work/166932536en
dc.identifier.otherORCID:/0000-0002-2480-2820/work/166933373en
dc.identifier.otherORCID:/0000-0002-1868-0206/work/180716954en
dc.identifier.otherORCID:/0000-0001-5231-6291/work/183306967en
dc.identifier.scopus85202176262en
dc.identifier.urihttps://hdl.handle.net/1885/733755516
dc.language.isoenen
dc.rights Copyright © 2024 The Author(s). Published by Elsevier Ltd.en
dc.sourceThe Lanceten
dc.titleFinancialisation: a 21st century commercial determinant of health equityen
dc.typeJournal articleen
dspace.entity.typePublicationen
local.bibliographicCitation.lastpage708en
local.bibliographicCitation.startpage705en
local.contributor.affiliationFriel, Sharon; School of Regulation & Global Governance, ANU College of Law, Governance and Policy, The Australian National Universityen
local.contributor.affiliationSchram, Ashley; School of Regulation & Global Governance, ANU College of Law, Governance and Policy, The Australian National Universityen
local.contributor.affiliationFrank, Nicholas; School of Regulation & Global Governance, ANU College of Law, Governance and Policy, The Australian National Universityen
local.contributor.affiliationArthur, Megan; School of Regulation & Global Governance, ANU College of Law, Governance and Policy, The Australian National Universityen
local.contributor.affiliationTownsend, Belinda; School of Regulation & Global Governance, ANU College of Law, Governance and Policy, The Australian National Universityen
local.contributor.affiliationGajurel, Hridesh; University of Queenslanden
local.identifier.citationvolume9en
local.identifier.pure1f776ea3-a45d-49cc-8ace-ccc25fc300a8en
local.identifier.urlhttps://www.scopus.com/pages/publications/85202176262en
local.type.statusPublisheden

Downloads